In the study, 9,711 patients who underwent hip and knee replacements were split into two groups. One group was treated strictly with aspirin after the surgery, while the other was only given the anticoagulant enoxaparin.
After 90 days, researchers evaluated both groups and found that venous thromboembolism occurred in 256 patients. The group treated strictly with aspirin were nearly twice as likely to develop VTE, according to the study.
The aspirin group saw a 3.45 percent VTE rate, while only 1.82 percent of the enoxaparin group experienced VTE.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
